New antibiotics to combat One Health AMR

Abiodun David Ogunniyi; Henrietta Venter; Mark A. T. Blaskovich

doi:10.1071/MA24022

RESEARCH ARTICLE (Open Access)

Previous Next Contents Vol 45(2)

New antibiotics to combat One Health AMR

Abiodun David Ogunniyi

^A , Henrietta Venter

^B and Mark A. T. Blaskovich

^C ^*

+ Author Affiliations

- Author Affiliations

^A Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance (CEAStAR) and Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, SA 5371, Australia. Email: david.ogunniyi@adelaide.edu.au

^B Clinical and Health Sciences, University of South Australia, Adelaide, 5000, Australia. Email: rietie.venter@unisa.edu.au

^C CEAStAR and The Community for Open Antimicrobial Drug Discovery (CO-ADD), Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Qld 4072, Australia. Email: m.blaskovich@uq.edu.au

Assoc. Prof. David Ogunniyi is a Fellow of the Australian Society for Microbiology and novel antibacterial pre-clinical experimental lead at the Australian Centre for Antimicrobial Resistance Ecology, The University of Adelaide. He currently focuses on developing bioluminescent mouse infection models for testing new antimicrobial drug classes. He has published 2 book chapters, >110 manuscripts and >25 scientific reports for Industry. At CEAStAR, Assoc. Prof Ogunniyi co-ordinates the novel antibacterial pre-clinical experimental strategy, industry engagement and training of HDRs and postdocs in bioluminescent mouse infection models.

Assoc. Prof. Rietie Venter is the Head of Microbiology in Clinical and Health Sciences at the University of South Australia. After obtaining PhD degree at the University of Leeds, Rietie spent 12 years at the University of Cambridge doing research on multidrug transporters, first as a postdoc and later leading her research group as a Dorothy Hodgkin Royal Society Fellow. She joined UniSA in 2012 where she is heading an internationally acclaimed research group on understanding and combating AMR.

Prof. Mark Blaskovich is an ‘antibiotic hunter’ and Director of Translation for the Institute for Molecular Bioscience at The University of Queensland, as well as Director of the ARC Industrial Transformation Training Centre, CEAStAR, and the antibiotic crowdsourcing initiative CO-ADD. A medicinal chemist with 15 years of industrial drug development experience, since 2010 he has been developing new antibiotics, non-antibiotic therapies and diagnostics to detect and treat resistant bacterial and fungal infections, including multiple industry collaborations focused on AMR.

^* Correspondence to: m.blaskovich@uq.edu.au

Microbiology Australia https://doi.org/10.1071/MA24022

Submitted: 28 March 2024 Accepted: 2 May 2024 Published: 23 May 2024

© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of the ASM. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY).

Abstract

The rise of antimicrobial resistance has been accompanied by a decline in the development of new antibiotics. In this article, we explore the current state of affairs and trends in both human- and animal-related antibiotic development activity, with distinct differences between the two sectors.

Keywords: AMR, antimicrobial drug development, antimicrobial pipeline, antimicrobial resistance, One Health.

Biographies

Assoc. Prof. David Ogunniyi is a Fellow of the Australian Society for Microbiology and novel antibacterial pre-clinical experimental lead at the Australian Centre for Antimicrobial Resistance Ecology, The University of Adelaide. He currently focuses on developing bioluminescent mouse infection models for testing new antimicrobial drug classes. He has published 2 book chapters, >110 manuscripts and >25 scientific reports for Industry. At CEAStAR, Assoc. Prof Ogunniyi co-ordinates the novel antibacterial pre-clinical experimental strategy, industry engagement and training of HDRs and postdocs in bioluminescent mouse infection models.

Assoc. Prof. Rietie Venter is the Head of Microbiology in Clinical and Health Sciences at the University of South Australia. After obtaining PhD degree at the University of Leeds, Rietie spent 12 years at the University of Cambridge doing research on multidrug transporters, first as a postdoc and later leading her research group as a Dorothy Hodgkin Royal Society Fellow. She joined UniSA in 2012 where she is heading an internationally acclaimed research group on understanding and combating AMR.

Prof. Mark Blaskovich is an ‘antibiotic hunter’ and Director of Translation for the Institute for Molecular Bioscience at The University of Queensland, as well as Director of the ARC Industrial Transformation Training Centre, CEAStAR, and the antibiotic crowdsourcing initiative CO-ADD. A medicinal chemist with 15 years of industrial drug development experience, since 2010 he has been developing new antibiotics, non-antibiotic therapies and diagnostics to detect and treat resistant bacterial and fungal infections, including multiple industry collaborations focused on AMR.

References

1 O’Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. The Wellcome Trust and Her Majesty’s Government, London, UK. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf

2 World Health Organization (2020) 10 global health issues to track in 2021. 24 December 2020. WHO. www.who.int/news-room/spotlight/10-global-health-issues-to-track-in-2021

3 Willyard C (2017) The drug-resistant bacteria that pose the greatest health threats. Nature 543, 15.
| Crossref | Google Scholar | PubMed |

4 Butler MS et al. (2013) Antibiotics in the clinical pipeline in 2013. J Antibiot 66, 571-591.
| Crossref | Google Scholar | PubMed |

5 Butler MS et al. (2017) Antibiotics in the clinical pipeline at the end of 2015. J Antibiot 70, 3-24.
| Crossref | Google Scholar | PubMed |

6 Butler MS, Cooper MA (2011) Antibiotics in the clinical pipeline in 2011. J Antibiot 64, 413-425.
| Crossref | Google Scholar | PubMed |

7 Butler MS et al. (2023) Antibiotics in the clinical pipeline as of December 2022. J Antibiot 76, 431-473.
| Crossref | Google Scholar | PubMed |

8 Butler MS, Paterson DL (2020) Antibiotics in the clinical pipeline in October 2019. J Antibiot 73, 329-364.
| Crossref | Google Scholar | PubMed |

9 Butler MS et al. (2022) Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob Agents Chemother 66, e0199121.
| Crossref | Google Scholar | PubMed |

10 Theuretzbacher U et al. (2020) The global preclinical antibacterial pipeline. Nat Rev Microbiol 18, 275-285.
| Crossref | Google Scholar | PubMed |

11 Theuretzbacher U et al. (2020) Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol 18, 286-298.
| Crossref | Google Scholar | PubMed |

12 Theuretzbacher U (2023) Evaluating the innovative potential of the global antibacterial pipeline. Clin Microbiol Infect
| Crossref | Google Scholar | PubMed |

13 European Medicines Agency (2024) Exblifep: cefepime / enmetazobactam. EMA, Amsterdam, Netherlands. https://www.ema.europa.eu/en/medicines/human/EPAR/exblifep#:~:text=The%20European%20Medicines%20Agency%20decided,for%20use%20in%20the%20EU (last updated 22 March 2024)

14 Stewart J (2024) Exblifep FDA approval history. Drugs.com. https://www.drugs.com/history/exblifep.html (last updated 12 March 2024)

15 Alm RA, Gallant K (2020) Innovation in antimicrobial resistance: the CARB-X perspective. ACS Infect Dis 6, 1317-1322.
| Crossref | Google Scholar | PubMed |

16 Pahil KS et al. (2024) A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature 625, 572-577.
| Crossref | Google Scholar | PubMed |

17 Zampaloni C et al. (2024) A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625, 566-571.
| Crossref | Google Scholar | PubMed |

18 Gugger MK, Hergenrother PJ (2024) A new type of antibiotic targets a drug-resistant bacterium. Nature 625, 451-452.
| Crossref | Google Scholar | PubMed |

19 Casiraghi A et al. (2020) Targeting bacterial cell division: a binding site-centered approach to the most promising inhibitors of the essential protein FtsZ. Antibiotics 9, 69.
| Crossref | Google Scholar | PubMed |

20 Antimicrobial Resistance Division, Global Coordination and Partnership (2022) Antibacterial agents in clinical and preclinical development: an overview and analysis. Technical document, 27 May 2022. World Health Organization. www.who.int/publications/i/item/9789240047655

21 Chai WC et al. (2020) Antimicrobial action and reversal of resistance in MRSA by difluorobenzamide derivatives targeted at FtsZ. Antibiotics 9, 873.
| Crossref | Google Scholar | PubMed |

22 Palma E et al. (2020) Antimicrobial resistance in veterinary medicine: an overview. Int J Mol Sci 21, 1914.
| Crossref | Google Scholar | PubMed |

23 Walther B et al. (2017) Multidrug-resistant opportunistic pathogens challenging veterinary infection control. Vet Microbiol 200, 71-78.
| Crossref | Google Scholar | PubMed |

24 Trott D (2013) β-lactam resistance in Gram-negative pathogens isolated from animals. Curr Pharm Des 19, 239-249.
| Google Scholar | PubMed |

25 Abraham S et al. (2014) Phylogenetic and molecular insights into the evolution of multidrug-resistant porcine enterotoxigenic Escherichia coli in Australia. Int J Antimicrob Agents 44, 105-111.
| Crossref | Google Scholar | PubMed |

26 Bhandari V, Suresh A (2022) Next-generation approaches needed to tackle antimicrobial resistance for the development of novel therapies against the deadly pathogens. Front Pharmacol 13, 838092.
| Crossref | Google Scholar | PubMed |

27 Tängdén T (2014) Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci 119, 149-153.
| Crossref | Google Scholar | PubMed |

28 Johansen TB et al. (2018) Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective. Sci Rep 8, 8538.
| Crossref | Google Scholar | PubMed |

29 Głowacka P et al. (2018) Brucella – virulence factors, pathogenesis and treatment. Pol J Microbiol 67, 151-161.
| Crossref | Google Scholar | PubMed |

30 Khan AU et al. (2019) Identification, genotyping and antimicrobial susceptibility testing of Brucella spp. isolated from livestock in Egypt. Microorganisms 7, 603.
| Crossref | Google Scholar | PubMed |

31 Swift BMC et al. (2019) Anthropogenic environmental drivers of antimicrobial resistance in wildlife. Sci Total Environ 649, 12-20.
| Crossref | Google Scholar | PubMed |

32 Lee T et al. (2021) Antimicrobial resistance in porcine enterococci in Australia and the ramifications for human health. Appl Environ Microbiol 87, e03037-20.
| Crossref | Google Scholar | PubMed |

33 Lee T et al. (2020) A three-year whole genome sequencing perspective of Enterococcus faecium sepsis in Australia. PLoS One 15, e0228781.
| Crossref | Google Scholar | PubMed |

34 Messele YE et al. (2022) Phenotypic and genotypic analysis of antimicrobial resistance in Escherichia coli recovered from feedlot beef cattle in Australia. Animals (Basel) 12, 2256.
| Crossref | Google Scholar | PubMed |

35 Messele YE et al. (2023) Phylogeny, virulence, and antimicrobial resistance gene profiles of Enterococcus faecium isolated from Australian feedlot cattle and their significance to public and environmental health. Antibiotics 12, 1122.
| Crossref | Google Scholar | PubMed |

36 Venter H (2019) Reversing resistance to counter antimicrobial resistance in the World Health Organisation’s critical priority of most dangerous pathogens. Biosci Rep 39, BSR20180474.
| Crossref | Google Scholar | PubMed |

37 Paterson DL (2024) Antibacterial agents active against Gram negative bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 33, 371-387.
| Crossref | Google Scholar | PubMed |

38 Venter H et al. (2015) RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 6, 377.
| Crossref | Google Scholar | PubMed |

39 Pisoni LA et al. (2023) Combined structure- and ligand-based approach for the identification of inhibitors of AcrAB-TolC in Escherichia coli. ACS Infect Dis 9(12), 2504-2522.
| Crossref | Google Scholar | PubMed |